Soft Tissue Sarcoma Case Study: Gracie Gonzales

After FidoCure® enabled treatment, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.

Soft Tissue Sarcoma Case Study: Gracie Gonzales

After FidoCure® enabled treatment, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.


After FidoCure® enabled treatment,  there was a significant reduction in the  size of the primary lesion and complete  resolution of thoracic metastasis.

Gracie, a 6-year-old spayed female  American Pitbull mix, presented to her primary veterinarian after noticing pain and  lameness associated with the left hind limb a few days earlier.

On physical exam a firm mass at the dorsomedial  aspect of the left quadriceps muscle was  appreciated around 7.5 cm in diameter. A fine needle  aspirate was performed, and the cytology was found  to be consistent with a soft tissue sarcoma. CBC/  Chemistry was found unremarkable, surgical excision  of the mass was performed. Histopathology revealed  a poorly differentiated soft tissue sarcoma with  mitotic index averaging 10 per HPF and neoplastic  cells extending to the surgical margins. Additional  therapeutic intervention was not elected at this time.

After several months, nodules were noted at  the previous surgical site indicating recurrence.  Consultation with a veterinary oncologist was  pursued. The oncologist noted that given the  location of the mass there was not a reasonable  surgical option to achieve complete resection or  cryo-reduction. Staging was recommended. The  presence of metastatic disease would suggest a poor  prognosis with a median survival time ﹤ 4 months.  Thoracic radiographs revealed multifocal pulmonary  metastatic disease.

Enter FidoCure®

After consideration of all treatment options,  Gracie’s family elected to enroll in FidoCure®.

Tumor tissue was sent for biopsy, as well as genomic  (DNA) and transcriptomic (RNA) sequencing.

The FidoCure® analysis indicated potential for a  combination approach with targeted therapies:

• Imatinib (VEGFR inhibitor)

10 mg/kg/day PO

• Trametinib (MEK/MEK2 inhibitor)

0.02 mg/kg/day PO

• Rapamycin (mTOR inhibitor)

0.1 mg/kg/day PO

Targeted therapies were prescribed by the patient’s  treating veterinarian. These medications were  administered orally by Gracie’s family at home.  After two weeks of treatment, a third medication  was introduced and subsequently discontinued  due to gastroenteritis at the initial dose. The other  medications were continued without side effects.

At the time of initial treatment the recurrent mass  was large and firm at the proximal medial thigh,  measuring approximately 7.5 cm X 7.5 cm. Two months  later, the mass measured 2.5 cm X 2.5 cm. Family  reported patient doing well and home with much  better mobility. There was no evidence of pulmonary  metastatic disease. Unremarkable thorax.


  • Advanced genomic testing previously available only to humans
  • A detailed report with personalized treatment options
  • A FidoCure® expert always available to consult with the treating veterinarian
  • Guidance on 14 precision therapies, FDA approved for humans

Dr. Gerry Post

Dr. Gerry Post has been practicing veterinary medicine for over 25 years specializing in veterinary oncology. He currently serves as Chief Veterinary Officer at the One Health Company.

Great! You've successfully subscribed.
Great! Next, complete checkout for full access.
Welcome back! You've successfully signed in.
Success! Your account is fully activated, you now have access to all content.